Meeting
2022 ASCO Annual Meeting
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.
Authors
Julia R. White
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Julia R. White , Stewart J. Anderson , Eleanor Elizabeth Harris , Eleftherios P. Mamounas , Daniel G. Stover , Patricia A. Ganz , Reshma Jagsi , Reena S. Cecchini , Carmen Bergom , Valerie Theberge , Mahmoud El-Tamer , Richard C. Zellars , Dean Alden Shumway , Guang-Pei Chen , Thomas B. Julian , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT04852887
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS613)
DOI
10.1200/JCO.2022.40.16_suppl.TPS613
Abstract #
TPS613
Poster Bd #
381a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.
First Author: Martin Sjöström
Poster
2023 ASCO Annual Meeting
LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis.
First Author: Elise Deluche
Poster
2021 ASCO Annual Meeting
Role of 21- gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy.
First Author: Neil Chandrabhan Chevli
First Author: Wendy R. Parulekar